Metraipolis › archive › dc_6c65b7cd4852

Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study — Europe PMC PMID:39404351

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39404351
DOI
10.1128/spectrum.01276-24
License (as archived)
solo-consultazione
Archived
2026-10-08T06:19:15.040Z
SHA-256 of the archived text
67f023299dd7b6e94caae79e85dc04de5a2bb5bc166a9933c28a630bc0525d92
Stable URL of this page
https://metraipolis.com/documento/dc_6c65b7cd4852

How to cite

Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study — Europe PMC PMID:39404351 — Europe PMC (en), https://europepmc.org/article/MED/39404351 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6c65b7cd4852 (Metraipolis archive dc_6c65b7cd4852, sha256 67f023299dd7b6e94caae79e85dc04de5a2bb5bc166a9933c28a630bc0525d92)
BibTeX
@misc{dc6c65b7cd4852,
  title = {Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study — Europe PMC PMID:39404351},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39404351},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6c65b7cd4852; sha256 67f023299dd7b6e94caae79e85dc04de5a2bb5bc166a9933c28a630bc0525d92},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39404351. Agents can read the archived copy with the MCP tool read_document.